Health Canada Approves Rybelsus for Heart Disease Prevention
Health Canada has approved an expanded indication for Rybelsus (semaglutide tablets), allowing the oral medication to be prescribed for reducing major adverse cardiovascular events in adults with Type 2 diabetes.
New Cardiovascular Indication
The regulatory approval expands beyond Rybelsus' original 2020 indication for glycemic control. The medication can now be prescribed specifically for adults with Type 2 diabetes who also have cardiovascular disease or are at high risk for heart disease.
This marks the first oral GLP-1 medication approved by Health Canada with a cardiovascular risk reduction indication. Ozempic and Wegovy, both injectable semaglutide formulations from Novo Nordisk, previously received similar cardiovascular approvals.
Regulatory Timeline
Rybelsus first received Health Canada approval in April 2020 as an adjunct to diet and exercise for improving glycemic control in adults with Type 2 diabetes mellitus. The new cardiovascular indication represents a significant expansion of the drug's approved uses in Canada.
The approval follows Health Canada's standard review process for new indications of existing medications. Healthcare providers can now prescribe Rybelsus specifically for patients meeting the cardiovascular risk criteria outlined in the product monograph.
Market Context
The expanded indication comes as Canada prepares for generic semaglutide competition. Nine generic applications are currently under Health Canada review through the generic semaglutide tracker, with first approvals expected by mid-2026.
However, generic versions will initially focus on the original diabetes indication. The cardiovascular indication may provide Novo Nordisk with continued differentiation in the Canadian market, even as generic injectable semaglutide becomes available.
Clinical Implications
The approval allows Canadian physicians to prescribe Rybelsus for a specific patient population: adults with Type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. This targeted indication may influence insurance coverage decisions and prescribing patterns.
As the only oral option in the semaglutide family with cardiovascular approval, Rybelsus may appeal to patients who prefer tablet formulations over injectable alternatives like Mounjaro.
Regulatory Status
The new indication adds to Health Canada's growing list of approved GLP-1 medication uses. Patients and healthcare providers can access detailed prescribing information through Health Canada's drug product database or consult the FAQ section for general medication information.
The approval does not affect current Rybelsus pricing or availability at Canadian pharmacies including Shoppers Drug Mart, Costco, and Walmart locations nationwide.
This article is for informational purposes only and does not constitute medical advice.
Get notified when generic prices go live
We’ll send one email the moment generic semaglutide prices are listed at Canadian pharmacies. No spam.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
